These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33387018)

  • 1. Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.
    Meza K; Biswas S; Zhu YS; Gajjar A; Perelstein E; Kumar J; Akchurin O
    Pediatr Nephrol; 2021 Jun; 36(6):1579-1587. PubMed ID: 33387018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
    Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
    Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
    Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
    Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
    Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
    Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CKD-MBD biomarkers and CKD progression: an analysis by the joint model.
    D'Arrigo G; Mallamaci F; Pizzini P; Leonardis D; Tripepi G; Zoccali C
    Nephrol Dial Transplant; 2023 Mar; 38(4):932-938. PubMed ID: 35790138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Plant-Based Protein Consumption on Kidney Function and Mineral Bone Disorder Outcomes in Adults With Stage 3-5 Chronic Kidney Disease: A Systematic Review.
    Burstad KM; Cladis DP; Wiese GN; Butler M; Hill Gallant KM
    J Ren Nutr; 2023 Nov; 33(6):717-730. PubMed ID: 37116624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
    Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activin A: a marker of mineral bone disorder in children with chronic kidney disease?
    Shankar R; Saha A; Dhull RS; Shroff R; Nangia A; Sharma S
    Pediatr Nephrol; 2024 Sep; 39(9):2773-2777. PubMed ID: 38744714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
    Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
    Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
    Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
    Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.
    Nitta K; Bieber B; Karaboyas A; Johnson DW; Kanjanabuch T; Kim YL; Lambie M; Hartman J; Shen JI; Naljayan M; Pecoits-Filho R; Robinson BM; Pisoni RL; Perl J; Kawanishi H
    Perit Dial Int; 2024 Jul; 44(4):275-286. PubMed ID: 38501163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
    Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
    Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
    Pazianas M; Miller PD
    J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.